CD146-targeted CAR-T cells

CD146-targeted CAR-T cell therapy is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy being developed by Essen Biotech for the treatment of advanced relapsed or refractory ovarian cancer. The therapy consists of patient-derived T cells that have been genetically modified to express a CAR targeting CD146 (also known as Melanoma Cell Adhesion Molecule, MCAM), a cell surface glycoprotein associated with tumor progression and metastasis in various solid tumors. In clinical development, this therapy is evaluated as part of a sequential treatment regimen following lymphodepleting chemotherapy with cyclophosphamide and fludarabine. The regimen involves the infusion of CD146-directed CAR-T cells followed by the administration of GPC3-directed CAR-T cells, a strategy intended to address tumor heterogeneity and improve therapeutic outcomes in patients with advanced ovarian cancer.

Other names

CD146 chimeric antigen receptor T cellsCD-146 chimeric antigen receptor T cellsCD 146 chimeric antigen receptor T cellsCD146-directed CAR-T cellsCD-146-directed CAR-T cellsCD 146-directed CAR-T cellsCD146 CAR-TCD-146 CAR-TCD 146 CAR-TCD146 chimeric antigen receptor T cells-Essen Biotech-ovarian cancerCD-146 chimeric antigen receptor T cells-Essen Biotech-ovarian cancerCD 146 chimeric antigen receptor T cells-Essen Biotech-ovarian cancer